EQUILLIUM, INC. Research and Development in Process
EQUILLIUM, INC. (EQ) reported Research and Development in Process of $23.05 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-05-11
- EQUILLIUM, INC. research and development in process for the quarter ending 2022-12-31 was $0.00.
- EQUILLIUM, INC. research and development in process for the quarter ending 2022-09-30 was $0.00.
- EQUILLIUM, INC. research and development in process for the quarter ending 2022-06-30 was $0.00.
- EQUILLIUM, INC. research and development in process for the quarter ending 2022-03-31 was $23.05M.
- EQUILLIUM, INC. research and development in process for fiscal 2022 was $23.05M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $0.00 derived: sum of 3 quarters · filed 2023-03-23 | $23.05M 10-K · filed 2023-03-23 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $23.05M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $23.05M 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $23.05M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |